Laura J. Hamill

Laura J. Hamill has deep experience in the biopharmaceutical industry, with over 30 years of global commercial experience in a variety of executive leadership positions. Most recently, she served as Executive Vice President, Worldwide Commercial Operations, for Gilead Sciences, Inc., where she was accountable for 2,200 employees and $22 billion in annual revenue and led the global commercial strategic direction and long-term planning.

Over an 18-year career at Amgen, Laura held a number of executive roles in the United States and internationally. In her last role as Senior Vice President and General Manager of the U.S., she was responsible for $18 billion in annual revenue and managed a team of 2,000 employees across all of Amgen’s therapeutic areas. She also served as the Chairperson of Amgen’s Senior Women’s Leadership Council.

Ms. Hamill is currently a member of the Board of Directors for, Pardes Biosciences, BB Biotech, Y-mAbs Therapeutics and AnaptysBio. She also is a board member for two private companies, Unchained Labs and Scilex Pharmaceuticals. Ms. Hamill holds a bachelor’s degree in business administration from the University of Arizona.